Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications

Rhea-AI Summary

Lunai Bioworks (NASDAQ: LNAI) executed a binding $20.0 million strategic transaction to acquire a blood-brain barrier delivery platform and CNS Alzheimer's drug assets from Clemann Group, structured as Series B Convertible Preferred at a fixed conversion price of $1.50 per share with a 19.9% beneficial ownership limitation.

The deal contains no variable pricing or resets and is described as NASDAQ compliant. The platform enables compounds to cross the BBB, activate selectively in the brain, and targets pathways tied to acetylcholinesterase modulation, strengthening Lunai's CNS Alzheimer’s pipeline and broader CNS development capabilities.

Positive

• Acquired BBB delivery platform valued via a $20.0M transaction
• Fixed conversion price of $1.50 per share strengthens equity clarity
• Platform targets acetylcholinesterase pathways, expanding CNS therapeutic reach

Negative

• Series B convertible preferred could cause up to 19.9% beneficial ownership if converted
• Issuance of convertible preferred may dilute existing shareholders upon conversion

Key Figures

Strategic transaction size: $20 million Conversion price: $1.50 per share Beneficial ownership limit: 19.9% +5 more

8 metrics

Strategic transaction size $20 million Binding strategic transaction with Clemann Group

Conversion price $1.50 per share Fixed conversion price for Series B Convertible Preferred

Beneficial ownership limit 19.9% Cap on beneficial ownership from preferred conversion

Price vs 52-week high -75.81% Distance from 52-week high of $1.66 before this news

Price vs 52-week low 165.37% Distance above 52-week low of $0.1513 before this news

Market cap $8,828,385 Market capitalization prior to the acquisition announcement

Daily move 10% 24-hour price change prior to publication

Relative volume 0.04x Today’s volume vs 20-day average before this news

Market Reality Check

Price: $0.4015 Vol: Volume 1,290,475 is well ...

low vol

$0.4015 Last Close

Volume Volume 1,290,475 is well below the 20-day average of 35,155,264, with relative volume at 0.04x. low

Technical Shares at $0.4015 are trading below the 200-day MA of $0.89 and remain 75.81% under the 52-week high.

Peers on Argus

No peer stocks were flagged in the momentum scanner, suggesting the 10% move in ...

No peer stocks were flagged in the momentum scanner, suggesting the 10% move in LNAI is stock-specific rather than part of a broader Biotechnology rotation.

Historical Context

5 past events · Latest: Mar 19 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 19	AI consortium launch	Positive	-4.2%	Announced Pathfinder Consortium targeting large U.S. countermeasure programs.
Feb 19	AI patent grant	Positive	-1.4%	Reported issuance of U.S. patent for core AI debiasing architecture.
Feb 13	Media platform exposure	Positive	-10.2%	CNBC segment highlighting AI platform for CNS and biodefense programs.
Feb 09	Shareholder letter	Positive	+24.7%	Outlined commercial Augusta AI platform and three prospective revenue engines.
Feb 09	AI oncology pilot	Positive	+24.7%	Launched AI pilot analyzing randomized Phase 2 colorectal cancer trial data.

Pattern Detected

Recent news has often been positive on technology and partnerships, yet price reactions have skewed negative or mixed, with only two of the last five items showing positive alignment.

Recent Company History

Over the last few months, Lunai Bioworks has emphasized its AI-driven discovery and biodefense strategy. On Feb 9, an AI oncology pilot and a shareholder letter highlighting three revenue engines both coincided with +24.67% moves. Later AI-focused updates on Feb 13, Feb 19, and the Mar 19 Pathfinder Consortium saw share declines, indicating that upbeat platform or AI announcements have not consistently translated into positive price action. Today’s CNS-focused acquisition adds a new therapeutic dimension to that story.

Market Pulse Summary

This announcement adds a BBB-based CNS delivery platform and Alzheimer’s assets via a $20M Series B ...

Analysis

This announcement adds a BBB-based CNS delivery platform and Alzheimer’s assets via a $20M Series B Convertible Preferred deal at a fixed $1.50 conversion price and a 19.9% ownership cap. It complements earlier AI- and biodefense-focused initiatives by adding a tangible therapeutic technology layer. Investors may track how Lunai integrates this acquisition with its AI discovery efforts and whether subsequent updates resemble prior mixed market reactions to positive news.

Key Terms

blood-brain barrier, bbb, central nervous system, cns

4 terms

blood-brain barrier medical

"acquire blood-brain barrier (BBB) delivery technology and central nervous system"

A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.

bbb medical

"to acquire blood-brain barrier (BBB) delivery technology and central nervous system"

bbb is a mid-level credit rating that signals an issuer or bond is financially stable but more vulnerable to adverse conditions than higher-rated peers. Think of it like a middle-of-the-road safety score for a car: it’s acceptable for everyday use but not the safest option in extreme conditions. For investors, a bbb rating matters because it influences borrowing costs, expected returns and portfolio rules about how much risk is acceptable, with lower ratings typically offering higher yields to compensate for greater risk.

central nervous system medical

"blood-brain barrier (BBB) delivery technology and central nervous system (CNS) Alzheimer's"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

cns medical

"delivery platform for CNS Alzheimer's therapies with broad CNS delivery applications"

CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.

AI-generated analysis. Not financial advice.

SACRAMENTO, Calif., March 26, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI) today announced it has executed a binding $20 million strategic transaction to acquire blood-brain barrier (BBB) delivery technology and central nervous system (CNS) Alzheimer's drug assets from the Clemann Group, SAS or its assignee.

The transaction is structured as Series B Convertible Preferred at a fixed conversion price of $1.50 per share, subject to a 19.9% beneficial ownership limitation. The structure contains no variable pricing or reset provisions, strengthening the Company's equity position while remaining NASDAQ compliant.

This acquisition brings a delivery platform to Lunai that addresses one of the most significant bottlenecks in CNS drug development: effectively transporting therapeutics into the brain. The underlying chemistry allows compounds to cross the blood-brain barrier, remain inactive in the body, and then activate specifically inside the brain. The platform's mechanism of action targets pathways central to acetylcholinesterase modulation in the brain, which are broadly implicated in neurological disease.

What makes this important is that it directly strengthens Lunai's CNS Alzheimer's pipeline by pairing precise biological target identification with a proven delivery method. At the same time, it expands the Company's ability to develop next-generation treatments across a broad range of CNS disorders where traditional drugs struggle to penetrate the brain effectively, offering the potential for improved safety and efficacy.

"This is a step-change in our capabilities," said David Weinstein, CEO of Lunai Bioworks. "We are now combining the ability to identify the right biology with a validated mechanism to deliver therapies directly into the brain. This has profound implications for how we treat Alzheimer's and other complex CNS diseases that have historically been unreachable."

About Lunai Bioworks
Lunai Bioworks (NASDAQ: LNAI) is an AI-driven life sciences company advancing drug discovery through its integrated platform. The Company combines clinical data, machine learning, and in vivo validation to identify disease biology and develop precision therapeutics. Lunai is focused on central nervous system diseases and oncology, with a mission to reduce development timelines and improve clinical success rates.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially. These risks include, but are not limited to, the ability to complete the transaction on anticipated terms, the successful integration of acquired technologies, the advancement of product candidates through development, regulatory approvals, and the Company's ability to maintain compliance with Nasdaq listing requirements. Lunai undertakes no obligation to update any forward-looking statements except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-executes-20m-strategic-transaction-at-fixed-1-50-conversion-acquiring-bbb-delivery-platform-for-cns-alzheimers-therapies-with-broad-cns-delivery-applications-302726205.html

SOURCE Lunai Bioworks Inc.

FAQ

What did Lunai Bioworks (LNAI) acquire in the March 26, 2026 transaction?

Lunai acquired a blood-brain barrier delivery platform and CNS Alzheimer’s drug assets. According to the company, the purchase was a binding $20.0 million Series B convertible preferred transaction to secure BBB delivery technology and related assets.

How is the $20M Lunai (LNAI) deal structured and what is the conversion price?

The transaction is structured as Series B Convertible Preferred with a fixed conversion price of $1.50 per share. According to the company, the structure includes a 19.9% beneficial ownership limitation and no price resets.

What does the 19.9% beneficial ownership limitation mean for LNAI shareholders?

The limitation caps beneficial ownership from conversion at 19.9%, potentially limiting outright control shifts. According to the company, this cap aims to balance financing with NASDAQ compliance while limiting single-party ownership.

How will the acquired BBB platform affect Lunai’s (LNAI) Alzheimer’s pipeline?

The platform is intended to improve brain delivery of therapeutics, strengthening Lunai’s CNS Alzheimer’s pipeline. According to the company, the chemistry allows selective brain activation and targets acetylcholinesterase-linked pathways relevant to neurological disease.

Does the LNAI transaction include variable pricing or reset provisions that affect shareholders?

No, the deal contains no variable pricing or reset provisions. According to the company, the fixed-price structure is designed to strengthen the equity position while remaining compliant with NASDAQ listing rules.